Yazar "Baycan, Ömer Faruk" seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim Yok
    Öğe
    The Impact of Plasma Glucose Levels on In-Hospital and Long-Term Mortality in Non-Diabetic Patients with ST-Segment Elevation Myocardial Infarction Patients
    (Duzce Univ, 2020) Tatlısu, Mustafa Adem; Kaya, Adnan; Keskin, Muhammed; Baycan, Ömer Faruk; Kayapınar, Osman; Çalışkan, Mustafa
    Objective: Increased admission plasma glucose can be seen in the acute phase of acute coronary syndromes (ACS). Hence, we performed a retrospective study to evaluate the admission plasma glucose concentration in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (pPCI) and who had no previous diagnosis of Diabetes Mellitus (DM). Methods: This retrospective study included 2504 consecutive confirmed STEMI patients treated with pPCI. The patients were divided into quantiles according to the admission glucose levels. Quantile I: 94 +/- 7 mg/dL (n = 626), quantile II: 112 +/- 5 mg/dL (n = 626), quantile III: 131 +/- 6 mg/dL (n = 626), quantile IV: 184 +/- 46 mg/dL (n = 626). Results: Patients with higher plasma glucose (Q4) had 6.6 times higher in-hospital all-cause mortality rates (95% CI: 3.95-9.30) and 3.12 times higher (95% CI: 2.2-4.4) long-term all-cause mortality rates than patients with lower plasma glucose (Q1-Q3), who had lower rates and were used as the reference. This significant relationship remained even after adjustment for all confounders. Conclusions: Even though glucose-lowering therapy is recommended in ACS patients with glucose levels >180 mg/dL, our results showed that high plasma glucose, even lower than 180 mg/dL, could predict in-hospital and long-term mortality.
  • Küçük Resim
    Öğe
    The Impact of Plasma Glucose Levels on In-Hospital and Long-Term Mortality in Non-Diabetic Patients with STSegment Elevation Myocardial Infarction Patients
    (2020) Tatlısu, Mustafa Adem; Kaya, Adnan; Keskin, Muhammed; Baycan, Ömer Faruk; Kayapınar, Osman; Çalışkan, Mustafa
    Objective: Increased admission plasma glucose can be seen in the acute phase ofacute coronary syndromes (ACS). Hence, we performed a retrospective study toevaluate the admission plasma glucose concentration in patients with ST-segmentelevation myocardial infarction (STEMI) undergoing primary percutaneous coronaryintervention (pPCI) and who had no previous diagnosis of Diabetes Mellitus (DM).Methods: This retrospective study included 2504 consecutive confirmed STEMIpatients treated with pPCI. The patients were divided into quantiles according to theadmission glucose levels. Quantile I: 94 ± 7 mg/dL (n= 626), quantile II: 112 ± 5mg/dL (n = 626), quantile III: 131 ± 6 mg/dL (n= 626), quantile IV: 184 ± 46 mg/dL(n= 626).Results: Patients with higher plasma glucose (Q4) had 6.6 times higher in-hospitalall-cause mortality rates (95% CI: 3.95–9.30) and 3.12 times higher (95% CI: 2.2–4.4)long-term all-cause mortality rates than patients with lower plasma glucose (Q1–Q3),who had lower rates and were used as the reference. This significant relationshipremained even after adjustment for all confounders.Conclusions: Even though glucose-lowering therapy is recommended in ACS patientswith glucose levels >180 mg/dL, our results showed that high plasma glucose, evenlower than 180 mg/dL, could predict in-hospital and long-term mortality.